top of page

About FAKnostics

Reimagining FAK Therapeutics and Diagnostics

Lab Experiment

Our Mission

To provide novel therapies and diagnostics utilizing our Focal Adhesion Kinase (FAK) platform technology to combat metastatic cancers and fibrosis, based on our efficient inhibitors and detectors of the FAK pathway.

Our Edge

Multiple companies have developed FAK inhibitors that target the kinase domain of FAK, but most have failed in clinical trials due to innate resistance mechanisms and poor specificity.

​

FAKnostics’ inhibitor targets the non-kinase domain, which has multiple advantages including: 1) delocalization of FAK from the focal adhesion, 2) disrupting of protein-protein complexes critical for drug resistance, 3) induction of cancer cell apoptosis, and 4) high cancer specificity. 

​

Our FAKnosTest® companion diagnostic is based on our proprietary FAK antibody thoroughly tested on thousands of clinical samples.

Our History

WGC Surgery 1988-2.jpeg

1988

Dr. William Cance, Surgical Oncologist, develops extensive and deep focal adhesion kinase expertise in diagnostics and therapeutics

metastasis.png

1993

Dr. William Cance, the "Godfather" of FAK, was the first to identify FAK in human tumors and report its overexpression

apoptosis.jpg

1996

First to show that attenuation of FAK causes apoptosis

antibody.png

2000

Discovery of FAK 4.47 monoclonal antibody used for immunohistochemical (IHC) diagnostic test

Drug Binding_edited_edited.jpg

2002

First to report major resistance mechanisms in FAK kinase inhibitors

CD0397889AA1B6E06DDC07256174F25E.jpg

1998

First to demonostrate importance of targeting FAK in cancer

FAK Roles.png

2004

FAKnostics became leaders in understanding the importance of FAK non-catalytic functions

Cancer Cells IF.png

2009

Demonstrated successful proof of principle for targeting non-catalytic FAK functions

protein.png

2013

Focus on structural approaches to target the FAK scaffold

Science Lab

2020-

Drug pipeline in cancer, wound care, and stress-induced fibrosis

Picture25.png

2020

Development of first-in-class peptide inhibitors of focal adhesion targeting (FAT) domain

FAK Antibody.tif

2018

Development of FAKnosTEST – companion diagnostic and prognostic marker for cancer

bottom of page